Announcements
- Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
- Karolinska Developments portföljbolag Biosergen får slutligt godkännande att utvärdera läkemedelskandidaten BSG005 i patienter med invasiv svampinfektion
- Karolinska Development breddar sin portfölj genom nyinvestering i BOOST Pharma
- Karolinska Development invests in BOOST Pharma, expanding its portfolio
- Karolinska Developments årsstämma 2024
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
More ▼
Key statistics
As of last trade Karolinska Development AB (2I9:FRA) traded at 0.103, 5.53% above its 52-week low of 0.0976, set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.103 |
---|---|
High | 0.103 |
Low | 0.103 |
Bid | 0.1134 |
Offer | 0.1484 |
Previous close | 0.1024 |
Average volume | 0.00 |
---|---|
Shares outstanding | 267.52m |
Free float | 92.74m |
P/E (TTM) | 11.63 |
Market cap | 387.37m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes, as of Jul 04 2024 07:04 BST.
More ▼